Molecular Vision Appoints Peter Woodford as Chairman

Strengthens Board in Preparation for Commercialisation

16-Feb-2009 - United Kingdom

Molecular Vision, a developer of quantitative point-of-care (POC) diagnostic devices, has announced the appointment of Peter Woodford as Non-Executive Chairman with immediate effect. The appointment serves to strengthen the Board as the Company prepares to commercialise its novel detection technology, focussing on low cost POC diagnostic tests in a miniaturised, easy-to-use, disposable format.

Mr Woodford has over 35 years’ experience in the diagnostics industry. Most recently he spent 15 years with Roche Diagnostics/Boehringer Mannheim, where he was responsible for a £1.2 billion budget for Roche Diabetes Care global strategic and commercial activities.

Molecular Vision’s previous Chairman, Dr Chris Wright, will continue to serve on the Board as a Non-Executive Director.

Other news from the department people

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

See the theme worlds for related content